Maze Therapeutics MAZE
NASDAQ MAZE
$35.45 +0.54 (+1.55%)
At close: Nov 10, 2026 · 4:00 PM EST

Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024)

Updated

Maze Therapeutics (MAZE) recorded Preferred Stock Liabilities of $508.09 million in Q4 2024, up 32.3% from the prior quarter.

Analysis

Maze Therapeutics (MAZE) Preferred Stock Liabilities (2024) Analysis & Trends

Starting with Q1 2024, Maze Therapeutics' Preferred Stock Liabilities history includes 4 quarters.

  • Per Business Quant, the preceding three quarters came in at $383.9 million (Q3 2024), $383.9 million (Q2 2024) and $383.9 million (Q1 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Maze Therapeutics 2.05 Bn 561.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 508.09 Mn
Sep 30, 2024 383.90 Mn
Jun 30, 2024 383.90 Mn
Mar 31, 2024 383.90 Mn
API Access

Maze Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=MAZE&period=max&api_key=YOUR_API_KEY